{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"description":"evaluated by IRC (PR + VGPR + CR + sCR)","groups":[{"description":"Enrolled patients will be treated with ATG-010( 100 mg/QW, oral ) with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5cycles.\n\nSVd (Selinexor+Bortezomib+dexamethasone): Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)","id":"OG000","title":"SVd (Selinexor+Bortezomib+Dexamethasone)"},{"description":"Enrolled patients will be treated with Bortezomib( 1.3 mg/QW, hypodermic injection ) +dexamethasone ( 20 mg/QW, oral ) about 13.5 cycles.\n\nVd (Bortezomib+dexamethasone): Vd Arm (\\~50): Bortezomib (Cycles 1-8 \\[BIW\\], Cycles ≥ 9 \\[QW\\]) + dexamethasone (Cycles 1-8 \\[Four times a week\\], Cycles ≥ 9 \\[BIW\\])","id":"OG001","title":"Vd (Bortezomib+Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From randomization until the earlier of IRC-confirmed PD or start of subsequent anti-myeloma therapy, assessed up to 2 years.","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}